| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA950: Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over |
|
Medicine details |
|
| Medicine name | nivolumab/relatlimab (Opdualag®) |
| Formulation | 240 mg/80 mg concentrate for solution for infusion |
| Reference number | 4050 |
| Indication | Untreated unresectable or metastatic melanoma |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/01/2024 |
| NICE guidance | |